Author: Los-Arcos, Ibai; Iacoboni, Gloria; Aguilar-Guisado, Manuela; Alsina-Manrique, Laia; DÃaz de Heredia, Cristina; Fortuny-Guasch, Claudia; GarcÃa-Cadenas, Irene; GarcÃa-Vidal, Carolina; González-Vicent, Marta; Hernani, Rafael; Kwon, Mi; Machado, Marina; MartÃnez-Gómez, Xavier; Maldonado, ValentÃn Ortiz; Pla, Carolina Pinto; Piñana, José Luis; Pomar, Virginia; Reguera-Ortega, Juan Luis; Salavert, Miguel; Soler-PalacÃn, Pere; Vázquez-López, Lourdes; Barba, Pere; Ruiz-Camps, Isabel
Title: Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper Cord-id: 0x9p1szg Document date: 2020_9_26
ID: 0x9p1szg
Snippet: Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both hematological and non-hematological diseases. Most of the patients receiving CAR-T therapy will develop fever at some point after infusion, mainly
Document: Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both hematological and non-hematological diseases. Most of the patients receiving CAR-T therapy will develop fever at some point after infusion, mainly due to cytokine release syndrome (CRS). The onset of CRS is often indistinguishable from an infection, which makes management of these patients challenging. In addition to the lymphodepleting chemotherapy and CAR T cells, the treatment of complications with corticosteroids and/or tocilizumab increases the risk of infection in these patients. Data regarding incidence, risk factors and prevention of infections in patients receiving CAR-T cell therapy are scarce. To assist in patient care, a multidisciplinary team from hospitals designated by the Spanish Ministry of Health to perform CAR-T therapy prepared these recommendations. We reviewed the literature on the incidence, risk factors, and management of infections in adult and pediatric patients receiving CAR-T cell treatment. Recommendations cover different areas: monitoring and treatment of hypogammaglobulinemia, prevention, prophylaxis, and management of bacterial, viral, and fungal infections as well as vaccination prior and after CAR-T cell therapy.
Search related documents:
Co phrase search for related documents- active infection and adenovirus coronavirus: 1, 2
Co phrase search for related documents, hyperlinks ordered by date